MIBC: FDA Broadens Pembrolizumab-Enfortumab Vedotin Use

The FDA has expanded the approved use of the pembrolizumab and enfortumab vedotin combination therapy for muscle-invasive bladder cancer (MIBC), broadening patient eligibility and treatment options in the US.

This Wire brief sits within Fusion42's coverage of Biotech.